Alberto Briganti, MD, PhD, discusses results from the PROTEUS substudy, evaluating perioperative apalutamide plus ADT vs surgery alone in high-risk localized or locally advanced prostate cancer.
|Articles|September 21, 2006
Bulking agent for female SUI receives approvable letter
Uroplasty, Inc. has received an approvable letter from the FDA relating to its pre-market approval application for Macroplastique implants for the treatment of female stress urinary incontinence.
Advertisement
Uroplasty, Inc. has received an approvable letter from the FDA relating to its pre-market approval application for Macroplastique implants for the treatment of female stress urinary incontinence.
The product is a soft tissue, injectable bulking agent for use in a minimally invasive, outpatient procedure. When a physician injects Macroplastique into the tissues surrounding the urethra, the increased bulk allows the urethra to close more effectively and prevents urine from leaking, the company said.
Advertisement
Related to this article
In a POTOMAC subgroup analysis, durvalumab plus BCG reduced the risk of high-risk recurrence or death by 44% vs BCG alone in patients with papillary-only, BCG-naive NMIBC.
Updated CAPItello-281 data showed a clinically meaningful benefit in OS when capivasertib was added to abiraterone and ADT in PTEN-deficient mHSPC.
Andrea Necchi, MD, discusses how results from the CA017-078 trials compares with other perioperative immunotherapy trials in muscle-invasive bladder cancer.
In TALAPRO-3, talazoparib plus enzalutamide improved rPFS vs placebo plus enzalutamide (HR, 0.48; P < .0001) in HRR-mutated mAPMN/S prostate cancer.
Final phase 3 CA017-078 data show perioperative nivolumab plus GC did not significantly improve pCR (39.1% vs 29.6%) or EFS (HR, 0.94) vs GC alone in MIBC.
Daniel Heng, MD, discusses final LITESPARK-011 results, including sustained PFS benefit with belzutifan plus lenvatinib vs cabozantinib in advanced ccRCC.
In the randomized phase 2 PE-PE trial, median relapse-free survival was 25.4 months with pembrolizumab plus surgery or SABR vs 11.0 months with local therapy alone.
Advertisement
Advertisement
Trending on Urology Times
1
Updated CAPItello-281 data show numerical OS benefit with capivasertib in PTEN-deficient mHSPC
2
Adding darolutamide to ADT and radiation improves MFS in very high-risk localized prostate cancer
3
Durvalumab plus BCG improves DFS in papillary-only, BCG-naïve NMIBC
4
Alberto Briganti, MD, PhD, on the PROTEUS substudy in high-risk prostate cancer
5